{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostatic+Cancer%2C+Castration-Resistant", "query": { "condition": "Prostatic Cancer, Castration-Resistant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 648, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostatic+Cancer%2C+Castration-Resistant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T20:56:59.874Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06193486", "title": "Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "MSGV1-PSCA-8T28Z", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2024-10-26", "completion_date": "2033-12-13", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06193486" }, { "nct_id": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Cancer", "Colorectal Cancer", "Triple Negative Breast Cancer", "Cervical Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Endometrial Cancer", "Sarcoma", "Squamous Cell Carcinoma of the Head and Neck", "Bladder Cancer", "Metastatic Castration Resistant Prostate Cancer", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "CPI-006", "type": "DRUG" }, { "name": "CPI-006 + ciforadenant", "type": "DRUG" }, { "name": "CPI-006 + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-04-25", "completion_date": "2023-02-19", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454451" }, { "nct_id": "NCT00974311", "title": "Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1199, "start_date": "2009-09-30", "completion_date": "2017-11-02", "has_results": true, "last_update_posted_date": "2018-12-11", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 98, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00974311" }, { "nct_id": "NCT03317392", "title": "Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 132, "start_date": "2019-02-04", "completion_date": "2027-02-16", "has_results": true, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 22, "location_summary": "La Jolla, California • Sacramento, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317392" }, { "nct_id": "NCT04631601", "title": "Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Acapatamab", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "AMG 404", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 65, "start_date": "2021-01-15", "completion_date": "2023-10-23", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04631601" }, { "nct_id": "NCT02565901", "title": "Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v7", "Metastatic Malignant Neoplasm in the Bone" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2016-02-29", "completion_date": "2020-06-16", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02565901" }, { "nct_id": "NCT03338790", "title": "An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" }, { "name": "rucaparib", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 292, "start_date": "2017-12-19", "completion_date": "2025-01-10", "has_results": true, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 19, "location_summary": "Daphne, Alabama • Rancho Mirage, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03338790" }, { "nct_id": "NCT03516812", "title": "Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Testosterone Enanthate", "type": "DRUG" }, { "name": "Testosterone Cypionate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2018-08-29", "completion_date": "2024-04-12", "has_results": true, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03516812" }, { "nct_id": "NCT03436485", "title": "Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "ODM-208", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 204, "start_date": "2018-03-19", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Minneapolis, Minnesota • Omaha, Nebraska + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436485" }, { "nct_id": "NCT03418324", "title": "Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "TRC105", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2018-03-05", "completion_date": "2019-11-06", "has_results": true, "last_update_posted_date": "2020-12-30", "last_synced_at": "2026-06-25T20:56:59.874Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03418324" } ] }